Table 1.
Clinical characteristics of patients used to measure EGFR mutation and PD-L1 expression status.
| Total (N = 3,816, %) | EGFR (N = 3,629, %) | PD-L1 (N = 873, %) | EGFR&PD-L1 (N = 818, %) | p-value | |
|---|---|---|---|---|---|
| Age (years) | 59.32 | 59.29 | 58.72 | 58.77 | 0.508 |
| Sex, N(%) | 0.143 | ||||
| Male | 2,067(54.17) | 1,955(53.87) | 471(53.95) | 449(54.89) | |
| Female | 1,749(45.83) | 1,674(46.13) | 402(46.05) | 369(45.11) | |
| Smoking status | 0.759 | ||||
| Current or former | 1,500(39.30) | 1,413(38.94) | 281(32.19) | 257(31.42) | |
| Never | 2,067(54.17) | 1,981(54.59) | 566(64.83) | 543(66.38) | |
| Unknown | 249(6.52) | 235(6.47) | 26(2.98) | 18(2.2) | |
| Family history of cancer | 0.503 | ||||
| Yes | 248(6.50) | 236(6.50) | 69(7.90) | 67(8.19) | |
| No | 3,353(87.87) | 3,188(87.85) | 791(90.61) | 745(91.08) | |
| Unknown | 215(5.63) | 205(5.65) | 13(1.49) | 6(0.73) | |
| Histopathology | 0.324 | ||||
| LUAD | 2,937(76.97) | 2,787(76.80) | 789(90.38) | 743(90.83) | |
| LUSC | 607(15.90) | 592(16.31) | 47(5.38) | 42(5.13) | |
| Other | 272(7.12) | 250(6.89) | 37(4.24) | 33(4.03) | |
| Stage | 0.497 | ||||
| I | 1,136(29.77) | 1,092(30.09) | 354(40.55) | 347(42.42) | |
| II | 284(7.44) | 272(7.50) | 68(7.79) | 63(7.7) | |
| III | 742(19.44) | 700(19.29) | 160(18.33) | 150(18.34) | |
| IV | 1,475(38.65) | 1,402(38.63) | 260(29.78) | 236(28.85) | |
| Unknown | 179(4.69) | 163(4.49) | 31(3.55) | 22(2.69) | |
| EGFR Mutation (%) | 0.934 | ||||
| EGFR Wild | 1,436(37.63) | 1,436(39.57) | – | 183(22.37) | |
| EGFR Mutant | 2,193(57.47) | 2,193(60.43) | – | 635(77.63) | |
| PD-L1 Expression (%) | 0.639 | ||||
| PD-L1- | 562(64.38) | – | 562(64.38) | 539(65.89) | |
| PD-L1 + | 311(35.62) | – | 311(35.62) | 279(34.11) | |
| Mutated EGFR Subtype (%) | 0.367 | ||||
| 19Del | 919(24.08) | 919(24.08) | – | – | |
| L858R | 1,090(28.56) | 1,090(30.04) | – | – | |
| Others | 184(4.82) | 184(5.07) | – | – | |
| Positive PD-L1 Expression (%) | 0.215 | ||||
| ≥50% | 268(7.02) | – | 268(30.70) | – | |
| 1-49% | 43(1.13) | – | 43(4.93) | – |
EGFR, epidermal growth factor receptor; PD-L1, programmed death ligand-1; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.